A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.